ArticleEuropean urology oncology2021
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in European urology oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.European urology · 2023Pooled it
- Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Trial
- Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.European radiology · 2026Article
- Clinical Impact of Germline Pathogenic Variants in High-risk Prostate Cancer Treated with Radiotherapy.European urology open science · 2026Article
- PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.International journal of molecular sciences · 2026Review
- Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.European urology · 2026Article
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.The Prostate · 2025Article
- Predisposition to prostate cancer and clinical implications in a real-life cohort.European journal of human genetics : EJHG · 2025Article
- Associations betweenJournal of medical genetics · 2025Article
- A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles.Targeted oncology · 2025Article
- Prostate cancer and genetic contributions.Andrology · 2025Review
- Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.JCO oncology practice · 2025Article
- Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review).Molecular medicine reports · 2025Review
- Long-Term Survival Following Chemoradiation in Locoregional Recurrent GermlineAdvances in radiation oncology · 2025Article
- Impact of prostate cancer screening in European ancestry un-affected men with germline DNA repair pathogenic variants.BJUI compass · 2025Article
- Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes.Nature communications · 2025Article
- Protein-truncating and rare missense variants inJournal of medical genetics · 2024Article
- Screening guidelines for individuals at increased risk for prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Review
- Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer.Journal of the National Cancer Institute · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 9 countries.
Questa KarlssonDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Mark N BrookDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Tokhir DadaevDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Sarah WakerellDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Edward J SaundersDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Kenneth MuirDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK; Warwick Medical School, University of Warwick, Coventry, UK.
David E NealNuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK; Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Robert J MacInnisCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Shannon K McDonnellDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Lisa Cannon-AlbrightDivision of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal; Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal; Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Paula PauloCancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Marta CardosoCancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Chad HuffDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Donghui LiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yu YaoDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer B PermuthDepartments of Cancer Epidemiology and Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
James Y DaiDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Elaine A OstranderCancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, USA.
Olivier CussenotGRC n°, AP-HP, Tenon Hospital, Sorbonne Universite, Paris, France; CeRePP, Tenon Hospital, Paris, France.
Géraldine Cancel-TassinGRC n°, AP-HP, Tenon Hospital, Sorbonne Universite, Paris, France; CeRePP, Tenon Hospital, Paris, France.
Josef HoegelInstitute for Human Genetics, University Hospital Ulm, Ulm, Germany.
Kathleen HerkommerDepartment of Urology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Johanna SchleutkerInstitute of Biomedicine, University of Turku, Turku, Finland; Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, Turku, Finland.
Teuvo L J TammelaDepartment of Urology, Tampere University Hospital, Tampere, Finland; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Venkat RathinakannanInstitute of Biomedicine, University of Turku, Turku, Finland.
Csilla SipekyInstitute of Biomedicine, University of Turku, Turku, Finland.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Markus AlyDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, Karolinska University Hospital, Solna, Stockholm, Sweden; Department of Urology, Karolinska University Hospital, Solna, Stockholm.
William B IsaacsJames Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA.
Jo L DickinsonUniversity of Tasmania, Menzies Institute for Medical Research, Hobart, Tasmania, Australia.
Liesel M FitzGeraldUniversity of Tasmania, Menzies Institute for Medical Research, Hobart, Tasmania, Australia.
Melvin L K ChuaDivisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore.
Tu Nguyen-DumontPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia.
PRACTICAL Consortium
Daniel J SchaidDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Melissa C SoutheyCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia.
Rosalind A EelesDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.
Zsofia Kote-JaraiDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK. Electronic address: zsofia.kote-jarai@icr.ac.uk.
Institute of Cancer Research · GBThe University of Texas MD Anderson Cancer Center · USUniversity of Turku · FIFred Hutch Cancer Center · USJohns Hopkins Hospital · USKarolinska Institutet · SEMayo Clinic · USAddenbrooke's Hospital · GBCancer Council Victoria · AUHôpital Tenon · FRInstituto Português de Oncologia Francisco Gentil · PTIPO Porto · PTKlinikum rechts der Isar · DEManchester Academic Health Science Centre · GBMayo Clinic in Arizona · USMenzies Institute for Medical ResearchMoffitt Cancer Center · USMonash Health · AUMonash University · AUNational Institutes of Health · US
Funding
Finding Genes for Human Prostate CancerZIAHG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2009 to 2021
$17.7MThe Genetic Basis of Aggressive Prostate Cancer: The Role of Rare VariationR01CA196931 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAIMAN, CHRISTOPHER ALAN, KOTE-JARAI, ZSOFIA · 2016 to 2020
$2.7MStatistical Genetics and Genomics for Epidemiologic ResearchR01CA222833 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SUN, WEI · 2018 to 2022
$2.2MCancer Research UK C5047/A17528NCI NIH HHS R01 CA196931NCI NIH HHS R01 CA222833
Abstract
backgroundGermline ATM mutations are suggested to contribute to predisposition to prostate cancer (PrCa). Previous studies have had inadequate power to estimate variant effect sizes.
objectiveTo precisely estimate the contribution of germline ATM mutations to PrCa risk. DESIGN, SETTING, AND
participantsWe analysed next-generation sequencing data from 13 PRACTICAL study groups comprising 5560 cases and 3353 controls of European ancestry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Variant Call Format files were harmonised, annotated for rare ATM variants, and classified as tier 1 (likely pathogenic) or tier 2 (potentially deleterious). Associations with overall PrCa risk and clinical subtypes were estimated. RESULTS AND LIMITATIONS: PrCa risk was higher in carriers of a tier 1 germline ATM variant, with an overall odds ratio (OR) of 4.4 (95% confidence interval [CI]: 2.0-9.5). There was also evidence that PrCa cases with younger age at diagnosis (<65 yr) had elevated tier 1 variant frequencies (p
conclusionsCarriers of pathogenic ATM variants have an elevated risk of developing PrCa and are at an increased risk for earlier-onset disease presentation. These results provide information for counselling of men and their families. PATIENT SUMMARY: In this study, we estimated that men who inherit a likely pathogenic mutation in the ATM gene had an approximately a fourfold risk of developing prostate cancer. In addition, they are likely to develop the disease earlier.
Indexed as
Genetic Predisposition to DiseaseProstatic NeoplasmsAtaxia Telangiectasia Mutated ProteinsGerm-Line MutationHumansMaleAtaxia Telangiectasia Mutated ProteinsATM protein, humanATM gene mutationsGenetic predispositionProstate cancerTargeted screening and therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT01221168ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.